The systematic erythalamus (SLE) is a complex self-immunological disease, which, like a “mysterious enemy” hidden in the body, strikes silently on various organs and systems of the human body, including skin, joints, kidneys, heart, blood, etc., causing many problems to the lives of patients. One of the most important concerns for many patients and their families is that they have a systematic erythalamus and that they need a life-long drug.
At present, most of the systematic erythalamus patients need long-term medication to control their condition, but “long-term” is not exactly equivalent to “lifelong”. This depends mainly on a number of factors, among which the severity of the patient ‘ s condition is one of the key factors. Patients with a lighter condition, such as light skin red spots, joint pains and a lack of vital organs, after a period of regulated treatment and effective control of the condition, are likely to experience a gradual reduction in the dose of the drug, under close medical supervision, and even a small number of patients can try to stop to observe after a longer period of stable conditions. However, while there is a possibility of a temporary stoppage, this group also needs to maintain regular re-diagnosis, as there is a risk of re-emergence.
On the contrary, for those with more serious conditions, such as severe kidney damage (renal lupus), heart disease and nervous system stress, long-term, sustained medication is often required to maintain stability and prevent further organ damage and deterioration. This is because, once damage to these important organs occurs, the process of repairing them is slow and complex, and the continued effects of the drugs are essential for controlling inflammation, inhibiting their own immune response and protecting the functioning of the organs.
Disease activity is also an important factor in the length of time spent on medication. Even for the same patient, the level of activity varies over time. When the disease is active and symptoms are clearly aggravated, such as heat, inefficiency, increased corrosive pain and increased protein urine, it is necessary to increase the dose of the drug or adjust the drug type to quickly control the condition, while the dose of the drug can be adjusted appropriately during the mitigation period, but usually it is not easily discontinued. Through regular laboratory examinations, such as the detection of indicators against double-chain DNA antibodies, reagent levels, blood sank, C reaction proteins, doctors are able to determine the activity of the disease with precision, thus developing individualized drug programmes for patients.
In addition, the differences between individuals cannot be ignored. The response to drugs varies from one patient to another, with some patients likely to be more sensitive to conventional drug treatment, with the conditions being more quickly controlled and stabilized, to a relatively short period of time, while others may differ in the tolerance and efficacy of the drug, owing to their own genetic factors, physical condition or the combination of other diseases, requiring longer-term drug treatment and even different treatment options.
It is noteworthy that, while the long-term use of drugs is a reality for many of the systematic erythalamus patients, new treatments and drugs are also emerging as medicine progresses. In the future, there may be more sophisticated, efficient and less reactive treatments that offer hope for a reduction in the time spent on drugs and even for the cure of diseases.
It is not possible to generalize whether systematic erythalamus use for life is necessary. Patients should maintain close communication with doctors, comply with medical instructions for standard treatment and regular review, build confidence in overcoming disease, deal with disease with a positive mentality, seek to maximize health, improve the quality of life with the help of medicines, allow disease to be effectively controlled, and regain sunlight and hope for their lives.
